Nifedipine for Inhibiting Threatened Preterm Labour in Siriraj Hospital

Authors

  • Saifon Chawanpaiboon Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Prapat Wanitpongpan Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Vitaya Titapant Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Sujin Kanokpongsakdi Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Chanchai Wantanasiri Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Kanjana Pimol Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Ratree Sirisomboon Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University

Keywords:

Nifedipine, tocolytic, threatened preterm labour

Abstract

Objective: To assess the success rate and effects on maternal and fetal outcomes of nifedipine administered as a tocolytic agent to women in threatened preterm labour.
Methods: During 1st January to 31st October, 2007, a total of 53 pregnant women with threatened preterm labour between 20-36 weeks participated in this study. All women were inhibited contraction with nifedipine 20 mg. orally every 30 minutes for 3 times then maintenance with nifedipine SR 20 mg. every 12 hours until 34 weeks. If a neonatal intensive care unit was not available, the inhibition of labour was prolonged until 36 weeks of gestation. If there is any complication with nifedipine, the inhibition of contraction was changed to be bricanyl intravenous form. If there were contraindications to the use of bricanyl, magnesium sulphate was used.
Results: 53 pregnant women with threatened preterm labour participated. The gestational age ranged from 28 to 35 weeks with the mean of 31.6 weeks of gestation. Failure of inhibition with nifedipine was found in 30/53 cases (57%) with a complication of maternal hypotension (90/60 mmHg) for 7 cases (13%) and one case of fetal distress. 23/53 (43%) cases were successful to inhibit contraction with nifedipine. Those patients who failed to inhibit contraction with nifedipine, 28 cases continued to inhibit contraction with bricanyl and 2 with magnesium sulphate (due to placenta previa). All were later successful to stop contraction with bricanyl and meagnesium sulphate. Ten pregnant women underwent caesarean section, 31 cases of normal delivery, 3 cases of vacuum extraction, and 2 cases referred to other hospitals (normal delivery). Seven cases were not delivered. The gestational age at delivery ranged from 29 to 40 weeks of gestation with the mean gestational age of 37.7 weeks. The babies’ weights ranged from 1,690 to 4,090 grams with the average body weight of 2,742 grams.
Conclusion: Nifedipine cannot be used successfully to inhibit contraction in threatened preterm labour. Other medications can be tried to minimize the incidence of preterm labour.

Downloads

Published

01-05-2008

How to Cite

Chawanpaiboon, S. ., Wanitpongpan, P. ., Titapant, V., Kanokpongsakdi, S. ., Wantanasiri, C. ., Pimol, K. ., & Sirisomboon, R. . (2008). Nifedipine for Inhibiting Threatened Preterm Labour in Siriraj Hospital. Siriraj Medical Journal, 60(3), 111–113. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/246366

Issue

Vol. 60 No. 3 (2008): May-Jun

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.